Indication (pathologie):
Candidemia
Identifiant SNOMED-CT:
432261003
Etudes cliniques
-
An open-label study to evaluate the efficacy and safety of APX001 in non-neutropenic patients with candidemia, with or without invasive candidiasis, inclusive of patients with suspected resistance to standard of care antifungal treatmentIndication (pathologie):CandidiasisIdentifiant SNOMED-CT:78048006Phase de l'étude: Phase IIRecrutement: Ouvert
-
A phase 3 randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of pimodivir in combination with the standard-of-care treatment in adolescent, adult, and elderly non-hospitalized subjects with influenza A infection who are at risk of developing complicationsIndication (pathologie):Influenza AIdentifiant SNOMED-CT:442696006Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A multicenter, multinational, double-blind, randomized, comparative study of the safety, tolerability, efficacy, and pharmacokinetics of CF-301 vs. Placebo in addition to standard of care antibacterial therapy for the treatment of adult patients with staphylococcus aureus bloodstream infections (Bacteremia) including right-sided endocarditisIndication (pathologie):Infection caused by Staphylococcus aureusIdentifiant SNOMED-CT:406602003Phase de l'étude: Phase IIRecrutement: Ouvert
-
Global point prevalence survey of antimicrobial consumption and resistance (Global-PPS)Indication (pathologie):AntimicrobialIdentifiant SNOMED-CT:250428009Recrutement: Ouvert
-
Phase 2b, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of intravenous vis410 in addition to oseltamivir (TAMIFLU®) compared with oseltamivir alone in hospitalized adults with influenza an infection requiring oxygen support. (VIS410-203)Indication (pathologie):Influenza AIdentifiant SNOMED-CT:442696006Phase de l'étude: Phase IIRecrutement: Ouvert